Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

NCT05066646 is registered in ClinicalTrials.gov with Nanjing IASO Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05066646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05066646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 1, 2020
Completion date
June 30, 2024
Enrollment
132 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma